Collegium Pharmaceutical ... (COLL)
29.54
-0.42 (-1.40%)
At close: Mar 27, 2025, 3:59 PM
29.82
0.95%
Pre-market: Mar 28, 2025, 07:00 AM EDT
Collegium Pharmaceutical Income Statement
| Year | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 |
| Revenue | 631.45M | 566.77M | 463.93M | 276.87M | 310.02M | 296.7M | 280.41M | 28.48M | 1.71M | n/a | n/a | n/a |
| Cost of Revenue | 254.1M | 240.6M | 254.44M | 126.25M | 130.18M | 193.66M | 165.68M | 2.6M | 213K | 171K | n/a | n/a |
| Gross Profit | 377.34M | 326.17M | 209.49M | 150.62M | 179.84M | 103.04M | 114.74M | 25.88M | 1.5M | -171K | n/a | n/a |
| Operating Income | 169.9M | 166.96M | -104.57M | -46.7M | -5.09M | -23.75M | -20.68M | -75.45M | -94.08M | -26.91M | -17.66M | -16.04M |
| Interest Income | 13.98M | 15.62M | 1.05M | 12K | 232K | 1.94M | 1.69M | 582K | n/a | n/a | n/a | n/a |
| Pretax Income | 98.57M | 75.73M | -28.85M | -3.37M | 27.58M | -22.72M | -39.13M | -74.86M | -94.18M | -27.25M | -17.92M | -16.2M |
| Net Income | 69.19M | 48.16M | -25M | 71.52M | 26.75M | -8.15M | -39.13M | -74.86M | -94.18M | -27.25M | -17.92M | -16.2M |
| Selling & General & Admin | 210.36M | 159.21M | 172.19M | 118.96M | 113.83M | 116.45M | 126.76M | 92.76M | 80.63M | 18.93M | 2.71M | 1.89M |
| Research & Development | n/a | n/a | 3.98M | 9.45M | 9.77M | 10.34M | 8.66M | 8.57M | 14.95M | 7.97M | 14.96M | 14.16M |
| Other Expenses | -2.91M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -94K | -348K | n/a | n/a |
| Operating Expenses | 207.45M | 150.71M | 176.17M | 128.41M | 123.6M | 126.79M | 135.42M | 101.33M | 95.58M | 26.91M | 17.66M | 16.04M |
| Interest Expense | 73.97M | 83.34M | 63.21M | 21.01M | 28.88M | 909K | 20.13M | 582K | 94K | 439K | 252K | 76K |
| Selling & Marketing Expenses | n/a | 7.41M | 11.74M | 4.19M | 5.37M | 116.45M | 126.76M | 92.76M | 80.63M | n/a | n/a | n/a |
| Cost & Expenses | 461.55M | 399.81M | 430.61M | 254.66M | 253.78M | 320.45M | 301.1M | 103.92M | 95.79M | 26.91M | 17.66M | 16.04M |
| Income Tax | 29.38M | 27.58M | -3.85M | -74.89M | 830K | -14.57M | -110.91M | -1.16M | 94K | -91K | 252K | 79K |
| Shares Outstanding (Basic) | 32.27M | 33.74M | 33.83M | 34.94M | 34.41M | 33.45M | 32.88M | 30.27M | 24.26M | 13.54M | 7.47M | 7.47M |
| Shares Outstanding (Diluted) | 40.42M | 41.79M | 33.83M | 41.05M | 35.15M | 33.45M | 32.95M | 30.27M | 24.26M | 13.54M | 7.47M | 7.47M |
| EPS (Basic) | 2.14 | 1.60 | -0.74 | 2.05 | 0.78 | -0.24 | -1.19 | -2.47 | -3.88 | -2.01 | -2.4 | -2.17 |
| EPS (Diluted) | 1.71 | 1.29 | -0.74 | 1.86 | 0.76 | -0.24 | -1.19 | -2.47 | -3.88 | -2.01 | -2.4 | -2.17 |
| EBITDA | 169.9M | 308.33M | 168.76M | 86.58M | 118.07M | -6.02M | 91.91M | -74.27M | -93.43M | -26.64M | -17.48M | -15.95M |
| Depreciation & Amortization | n/a | 149.26M | 134.39M | 68.94M | 61.61M | 15.8M | 110.91M | 594K | 655K | 171K | 187K | 169K |